News >

PACIFIC Immunotherapy Data Open Research Opportunities in Stage III NSCLC

Ellie Leick
Published: Wednesday, Aug 07, 2019

Drew Moghanaki, MD, MPH

Drew Moghanaki, MD, MPH

Results from the phase III PACIFIC trial showed an improvement in overall survival with durvalumab (Imfinzi), leading to a new standard of care for select patients with stage III non–small cell lung cancer. Now, Drew Moghanaki, MD, MPH, is asking more questions as the community looks to the future of treatment for this patient population.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication